Advertisement
AMGN vs GILD
Which Stock Would AI Choose? Amgen (AMGN) vs. Gilead Sciences (GILD) Stock Comparison
Key Takeaways
- AMGN has delivered stronger year-to-date returns of approximately 19% compared to more modest gains for GILD, reflecting robust momentum in recent market activity.
- Both biotechnology companies are scheduled to report second-quarter 2026 earnings on August 4, providing near-term catalysts for investor sentiment.
- AMGN benefits from a diversified portfolio in oncology, cardiovascular, and inflammation therapies, while GILD maintains leadership in HIV treatments and expanding oncology assets.
- Recent weeks show AMGN with positive performance trends outperforming broader benchmarks, whereas GILD has seen steadier but lower-volatility movement supported by pipeline updates.
- Market positioning favors AMGN on relative strength and growth metrics, though GILD offers a lower valuation multiple and consistent dividend yield around 2.5%.
- Sector exposure in biotechnology highlights trade-offs between innovation-driven growth at AMGN and established antiviral franchise stability at GILD.
Introduction
This comparison examines AMGN and GILD, two prominent biotechnology stocks, to help traders and investors assess relative performance, business drivers, and market positioning in the current environment. The analysis focuses on recent developments over the past several weeks alongside broader trends, offering insights relevant to those evaluating sector allocation, momentum strategies, or long-term holdings in healthcare equities. Readers interested in data-driven contrasts between established biopharma names will find this overview particularly useful for informed decision-making.
AMGN Overview and Recent Performance
Amgen Inc. is a leading biotechnology company focused on discovering, developing, and commercializing innovative therapies in oncology, cardiovascular disease, inflammation, and rare diseases. In recent market activity, AMGN shares have traded near record levels around $385, reflecting solid year-to-date gains of roughly 19% that outpaced the S&P 500. Performance over recent weeks has shown resilience, with periods of gains amid broader market fluctuations, supported by pipeline progress and consistent dividend payouts. Investor sentiment has remained constructive due to the company’s diversified revenue base and upcoming earnings release, which analysts expect to highlight steady demand across key franchises. Relative stability and outperformance versus benchmarks have contributed to positive positioning in the biotechnology sector.
GILD Overview and Recent Performance
Gilead Sciences, Inc. specializes in antiviral therapies, particularly HIV treatments, alongside growing oncology and inflammation portfolios. The stock has traded near $130 in recent sessions, with more modest gains over the past month of approximately 1% amid steady sector conditions. Recent market activity reflects pipeline advancements in long-acting HIV regimens and oncology combinations, supporting a stable but less aggressive price trajectory compared to peers. GILD maintains a competitive dividend yield near 2.5% and trades at a forward price-to-earnings ratio around 17-18, appealing to value-oriented participants. Upcoming second-quarter results on August 4 are anticipated to provide updates on product demand and development milestones, influencing short-term sentiment within the biotechnology space.
Trending AI Robots
Tickeron offers a curated selection of AI-powered trading robots designed to navigate thousands of tickers across diverse market conditions. While hundreds of bots are available with varying strategies, timeframes, and performance profiles, only the strongest performers suited to prevailing trends earn placement in the Trending AI Robots section. Available statistics highlight compelling ranges, including annualized returns reaching up to +241% and win rates of 70–80% for select high-ranked agents, alongside metrics such as Sharpe ratios and profit factors that allow users to evaluate risk-adjusted outcomes. These robots employ distinct approaches, from high-frequency scalping to longer-term trend following, each optimized for specific assets and market regimes. For traders seeking data-backed automation tools, reviewing the full suite can reveal opportunities aligned with individual styles. Trending AI Robots
Head-to-Head Comparison
In terms of business models, AMGN emphasizes a broad therapeutic pipeline with multiple growth drivers in high-value areas such as oncology and cardiometabolic treatments, whereas GILD derives significant stability from its established HIV franchise while advancing targeted oncology assets. Recent momentum favors AMGN, which has posted stronger year-to-date and multi-week returns relative to GILD’s steadier profile. Risk factors include clinical trial outcomes and regulatory decisions for both, though AMGN faces greater exposure to patent dynamics across a wider portfolio. Sector exposure remains similar within biotechnology, yet market sentiment has tilted toward AMGN amid superior relative performance and analyst attention ahead of earnings. Trade-offs emerge in valuation, with GILD presenting a lower multiple that may attract income-focused investors, balanced against AMGN’s demonstrated growth consistency.
Tickeron AI Verdict
Based on observable factors including stronger trend consistency, superior recent relative performance, and favorable positioning ahead of earnings, Tickeron’s AI would currently assign a probabilistic edge to AMGN over GILD. The assessment incorporates metrics such as momentum stability and sector catalysts, suggesting AMGN may offer more compelling alignment with prevailing market dynamics, though outcomes remain subject to broader volatility and individual risk considerations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and GILD is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileGILD’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- GILD’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while GILD’s TA Score has 4 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 4 bearish.
- GILD’s TA Score: 4 bullish, 3 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while GILD (@Pharmaceuticals: Major) price change was +3.87% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.23%. For the same industry, the average monthly price growth was +0.30%, and the average quarterly price growth was +2.34%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
GILD is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.23% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | GILD | AMGN / GILD | |
| Capitalization | 225B | 172B | 131% |
| EBITDA | 16.7B | 14.5B | 115% |
| Gain YTD | 28.699 | 14.111 | 203% |
| P/E Ratio | 25.79 | 17.84 | 145% |
| Revenue | 37.2B | 29.7B | 125% |
| Total Cash | 12B | N/A | - |
| Total Debt | 57.3B | 22.2B | 258% |
AMGN | GILD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 13 | 17 | |
SMR RATING 1..100 | 12 | 24 | |
PRICE GROWTH RATING 1..100 | 9 | 50 | |
P/E GROWTH RATING 1..100 | 40 | 79 | |
SEASONALITY SCORE 1..100 | 85 | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (7) in the Biotechnology industry is in the same range as AMGN (8). This means that GILD’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (13) in the Biotechnology industry is in the same range as GILD (17). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is in the same range as GILD (24). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
AMGN's Price Growth Rating (9) in the Biotechnology industry is somewhat better than the same rating for GILD (50). This means that AMGN’s stock grew somewhat faster than GILD’s over the last 12 months.
AMGN's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for GILD (79). This means that AMGN’s stock grew somewhat faster than GILD’s over the last 12 months.
| AMGN | GILD | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 60% | N/A |
| Stochastic ODDS (%) | 3 days ago 49% | 3 days ago 50% |
| Momentum ODDS (%) | 3 days ago 55% | 3 days ago 64% |
| MACD ODDS (%) | 3 days ago 69% | 3 days ago 74% |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 60% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 63% |
| Advances ODDS (%) | 4 days ago 60% | 3 days ago 62% |
| Declines ODDS (%) | 14 days ago 50% | 11 days ago 49% |
| BollingerBands ODDS (%) | 3 days ago 49% | 3 days ago 48% |
| Aroon ODDS (%) | 3 days ago 55% | 3 days ago 46% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -0.63% | ||
| BIIB - AMGN | 62% Loosely correlated | -0.39% | ||
| PFE - AMGN | 52% Loosely correlated | -0.04% | ||
| GILD - AMGN | 52% Loosely correlated | +0.16% | ||
| MRK - AMGN | 50% Loosely correlated | +0.21% | ||
| ABBV - AMGN | 47% Loosely correlated | -0.54% | ||
More | ||||